prostate cancer Prostate carcinoma
Conditions
Interventions
Infusion of Lutetium-177-PSMA-617
Sponsors
Radboud Universitair Medisch Centrum
Eligibility
Age
18 Years to 99 Years
Inclusion criteria
Inclusion criteria: - Histological proven adenocarcinoma of the prostate ;- Prior local therapy for prostate cancer;- Biochemical recurrence or clinical progression after local therapy (PSA > 0.2 µg/l), PSA-DT < 6 months);- 68Ga-PSMA-PET-CT positive metastases in bones and/or lymph nodes (N1/M1ab): *1, maximally 10 metastases (minimal lesion size 1 cm to enable adequate dosimetry studies) ;- Local treatment for oligometastases with radiotherapy or surgery appears to be no option anymore (due to prior treatment or the location of the metastatic lesions);- No prior hormonal therapy or chemotherapy; testosteron > 1.7 nmol/l. ;Exception: local prostate cancer treated with local radiotherapy plus adjuvant ADT; these patients need to be stopped with ADT at least 3 months;- No visceral metastases ;- Laboratory values: ;* White blood cells * 3.5 x 10^9/l ;* Platelet count * 150 x 10^9/l ;* Hemoglobin * 6 mmol/l ;* ASAT, ALAT * 3 x ULN ;* MDRD-GFR * 60 ml/min ;-Signed informed consent
Exclusion criteria
Exclusion criteria: - A known subtype other than prostate adenocarcinoma;- Any medical condition present that in the opinion of the investigator will affect patients* clinical status when participating in this trial. ;- Prior hip replacement surgery potentially influencing performance of PSMA PET/CT and nanoMRI;- Contra-indication for MRI imaging (claustrophobia, implanted electric and electronic devices (heart pacemakers, insulin pumps, implanted hearing aids, neurostimulators), intracranial metal clips, metallic bodies in the eye)
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| - To calculate the doses delivered by Lutetium-177-PSMA-617 radioligand therapy in patients with low volume, hormone sensitive metastatic prostate cancer - To determine the toxicity (focusing on radiation doses to organs at risk) of Lutetium-177-PSMA-617 radioligand therapy in patients with low volume, hormone sensitive metastatic prostate cancer | — |
Secondary
| Measure | Time frame |
|---|---|
| - To evaluate the clinical efficacy of multiple doses Lutetium-177-PSMA-617 radioligand therapy in patients with low volume, hormone sensitive metastatic prostate cancer by: 1. the changes in PSA values after Lutetium-177-PSMA-617 RLT 2. the changes on uptake of Gallium-68-PSMA-617 PET/CT before and 6 months after Lutetium-177-PSMA-617 RLT 3.To evaluate the changes in number and size of metastatic lymph nodes on nano-MRI before and 3 months after Lutetium-177-PSMA-617 RLT) - To evaluate the quality of life after Lutetium-177-PSMA-617 RLT | — |
Countries
Netherlands
Outcome results
None listed